HC Wainwright Predicts Surrozen’s Q1 Earnings (NASDAQ:SRZN)

Surrozen, Inc. (NASDAQ:SRZN) – Investment analysts at HC Wainwright raised their Q1 2025 EPS estimates for Surrozen in a research note issued to investors on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($1.09) per share for the quarter, up from their prior estimate of ($2.71). HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share. HC Wainwright also issued estimates for Surrozen’s Q2 2025 earnings at ($1.07) EPS, Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($1.03) EPS, FY2025 earnings at ($4.22) EPS, FY2026 earnings at ($4.63) EPS, FY2027 earnings at ($5.50) EPS, FY2028 earnings at ($6.53) EPS and FY2029 earnings at ($7.15) EPS.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings results on Monday, March 31st. The company reported ($9.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.54) by ($6.56). The firm had revenue of $0.66 million during the quarter.

Separately, Guggenheim upgraded shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price objective for the company in a research note on Friday, January 3rd.

Surrozen Stock Performance

SRZN opened at $9.35 on Monday. The firm has a market cap of $30.39 million, a P/E ratio of -0.43 and a beta of 0.69. The business has a 50 day moving average price of $11.24 and a 200 day moving average price of $11.09. Surrozen has a twelve month low of $6.00 and a twelve month high of $18.17.

Institutional Trading of Surrozen

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in Surrozen by 26.1% during the fourth quarter. Geode Capital Management LLC now owns 22,391 shares of the company’s stock worth $321,000 after buying an additional 4,630 shares in the last quarter. Trustees of Columbia University in the City of New York bought a new stake in shares of Surrozen in the 4th quarter worth approximately $688,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Surrozen during the 4th quarter worth approximately $928,000. Regents of The University of California bought a new stake in shares of Surrozen during the fourth quarter valued at approximately $1,912,000. Finally, Stonepine Capital Management LLC raised its stake in shares of Surrozen by 24.7% in the fourth quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company’s stock valued at $1,969,000 after purchasing an additional 27,200 shares in the last quarter. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, major shareholder Group Gp Lp Column III acquired 1,034,482 shares of the stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average price of $11.60 per share, for a total transaction of $11,999,991.20. Following the completion of the purchase, the insider now owns 795,411 shares in the company, valued at approximately $9,226,767.60. The trade was a -432.71 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 43.50% of the stock is currently owned by company insiders.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.